Resident Review Workshop

Sponsored by

Thursday, October 18th

8:00 am – 12:00 pm


  • VCS member residents:  COMPLIMENTARY
  • Non-member residents:  $35
  • Member or non-member interns, students and technicians:  $35
  • Member or non-member professionals:  $50

Speaker #1:  Dr. Tim Fan
University of Illinois

Presentation Title: Hallmarks of cancer molecular vignettes

Speaker Notes:  http://vetcancersociety.org/conference/wp-content/uploads/sites/2/2018/10/Tim-Fan-Resident-Review-Presentation-Speaker-Slides.pdf

Presentation Synopsis:  The biology of cancer is extremely complex, yet key and conserved molecular characteristics are shared among diverse cancer histologies. These deranged cellular properties have been identified as “Hallmarks of Cancer”, and the fundamental understanding of these recurrent cancer-associated properties are essential for both clinicians and researchers alike, and with greater knowledge of these cellular perturbations promising to improve the future management of cancer in veterinary species. During this seminar presentation, the underpinnings responsible for each of these “Hallmarks” will be explained at a molecular level and key clinical examples in the published veterinary literature will be highlighted to emphasize the current state of understanding for these neoplastic processes in spontaneous tumors in companion animals.

About the Presenter: Dr. Fan received his Doctor of Veterinary Medicine Degree at Virginia-Maryland Regional College of Veterinary Medicine in 1995 and completed a Small Animal Rotating Internship at the University of Illinois in 1996.  Following the completion of his internship, Dr. Fan fulfilled a Small Animal Internal Medicine Residency at Cornell University then returned to the University of Illinois to receive advanced clinical training in the subspecialty of Medical Oncology.  Dr. Fan completed his Board Certification in Internal Medicine in 2000 and in Medical Oncology in 2001.  Following the completion of Dr. Fan’s clinical training, he pursued and completed a PhD in Tumor Immunology, whereby he investigated the anticancer effects of cytokine manipulation strategies for the treatment of locally-invasive and metastatic tumors in mouse models of disease. Dr. Fan now is a Professor in the Department of Veterinary Clinical Medicine and a core faculty member at the Carl R. Woese Institute for Genomic Biology within the Anticancer Discovery from Pets to People theme that focuses research in the field of Immuno-Oncology and Small Molecular Therapeutics through the inclusion of pet dogs and cats with cancer.  Dr. Fan’s training as a scientist and veterinarian, has allowed him the opportunity to rapidly investigate and translate novel treatment strategies in companion animals with spontaneously-arising cancers, and conduct meaningful comparative oncology research which is hoped to eventually aid in treating cancer in not only pet animals, but also human beings.

 


 

Speaker #2:  Dr. Nicola Mason
University of Pennsylvania

Presentation Title: Clinical applications of immunotherapy in veterinary medicine

Speaker Notes: Two files below

https://www.dropbox.com/s/rbxh0adra32apyt/Resident%20Review%20vcs%202018.pdf?dl=0

https://www.dropbox.com/s/nc5t1qigbleizoh/Resident%20Review%20vcs%202018.ppt?dl=0

About the Presenter: Dr. Mason is a board certified veterinary internist and immunologist with extensive experience in the performance of immunotherapy clinical trials and evaluation of immunological responses in dogs with spontaneous cancer. In her career, Dr. Mason has worked on developing the canine model for evaluating chimeric antigen receptor T cell therapies and has successfully translated several promising strategies to generate anti-tumor immunity from the lab and pre-clinical murine models into client owned dogs with lymphoma, osteosarcoma and hemangiosarcoma. Dr. Mason has been actively involved in evaluating the immunological consequences of immune–based therapies in client owned dogs for over 10 years, and she has extensive experience in flow cytometric phenotyping of canine T cells and functional assays including ELISpot and cytotoxicity assays to investigate canine T cell responses. Her in vitro and in vivo work with RNA transfected CD40-activated B cells and recombinant Listeria technology has shown that tumor-specific immune responses can be generated and effectively measured ex vivo in dogs with spontaneous cancers. Both systems, first brought into the canine clinic by Dr. Mason, represent robust platforms to induce and evaluate antigen specific immune responses in dogs and determine their safety and therapeutic efficacy. Dr. Mason’s lab actively works to develop and validate diagnostic and therapeutic reagents for dogs including anti-canine antibodies, canine scFv phage display libraries and canine CAR T cells. Her lab has developed multiple SOPs for the use of these and other reagents in the laboratory and canine clinic. Dr. Mason also leads the recently formed NIH/NCI funded Coordinating Center for Canine Cancer Immunotherapy Trials.